126111-14-6

Basic information

• Product Name: L-Proline, 4,4-difluoro-, methyl ester (9CI)
• Synonyms: L-Proline, 4,4-difluoro-, methyl ester (9CI)
• CAS NO: 126111-14-6
• Molecular Formula: C₆H₉F₂NO₂
• Molecular Weight: 165.1379664
• Product Categories: GLYCINESCAFFOLD;PYRROLE
• Mol File: 126111-14-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 175.0±40.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• PKA: 4.59±0.10(Predicted)
• CAS DataBase Reference: L-Proline, 4,4-difluoro-, methyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: L-Proline, 4,4-difluoro-, methyl ester (9CI)(126111-14-6)
• EPA Substance Registry System: L-Proline, 4,4-difluoro-, methyl ester (9CI)(126111-14-6)

Safety Data

• Hazardous Substances Data: 126111-14-6(Hazardous Substances Data)

Upstream product

• 796095-60-8 (2S)-1-tert-butoxycarbonyl-2-(methoxycarbonyl)-4-hydroxyazacyclopentane 
• 1001383-50-1 trans-4-hydroxy-L-proline methyl ester 
• 51-35-4 4-hydroxyproline 
• 203866-17-5 1-tert-butyl 2-methyl (2S)-4,4-difluoropyrrolidine-1,2-dicarboxylate 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 102195-80-2 (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate 

Downstream Products

• 475561-89-8 4-fluoro-1H-pyrrole-2-carboxylic acid methyl ester 
• 1145663-10-0 methyl (2S)-N-(4-benzyloxy-5-methoxy-2-nitrobenzoyl)-4,4-difluoropyrrolidine-2-carboxylate 
• 1445984-75-7 (S)-1-(2,5-dichlorobenzyl)-4,4-difluoropyrrolidine-2-carboxylic acid 
• 1445984-74-6 (S)-methyl 1-(2,5-dichlorobenzyl)-4,4-difluoropyrrolidine-2-carboxylate 
• 1419387-85-1 C₄₇H₅₆F₄N₄O₁₂ 
• 475561-90-1 4-fluoro-pyrrole-2-carboxylic acid 

Relevant articles and documents

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.

Remarkable enhancement in the DNA-binding ability of C2-fluoro substituted pyrrolo[2,1-c][1,4]benzodiazepines and their anticancer potential

C2-Fluoro substituted DC-81, and its dimers that comprise of two C2-fluoro substituted DC-81 subunits tethered to their C8-position through simple alkane spacers as well as piperazine moiety side-armed with symmetrical alkyloxy spacers have been designed